$18.93
3.07% day before yesterday
Nasdaq, Dec 27, 09:47 pm CET
ISIN
US04280A1007
Symbol
ARWR

Arrowhead Pharmaceuticals, Inc. Stock price

$18.96
-7.19 27.50% 1M
-6.73 26.20% 6M
-11.64 38.04% YTD
-12.07 38.90% 1Y
-47.34 71.40% 3Y
-45.97 70.80% 5Y
+12.35 186.62% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.57 2.92%
ISIN
US04280A1007
Symbol
ARWR
Sector
Industry

Key metrics

Market capitalization $2.36b
Enterprise Value $2.54b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 714.32
P/S ratio (TTM) P/S ratio 664.58
P/B ratio (TTM) P/B ratio 12.72
Revenue growth (TTM) Revenue growth -98.52%
Revenue (TTM) Revenue $3.55m
EBIT (operating result TTM) EBIT $-601.08m
Free Cash Flow (TTM) Free Cash Flow $-604.32m
Cash position $680.96m
EPS (TTM) EPS $-5.00
P/E forward negative
P/S forward 7.48
EV/Sales forward 8.04
Short interest 8.91%
Show more

Is Arrowhead Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Arrowhead Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast:

9x Buy
64%
5x Hold
36%

Analyst Opinions

14 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast:

Buy
64%
Hold
36%

Financial data from Arrowhead Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3.55 3.55
99% 99%
100%
- Direct Costs 19 19
49% 49%
524%
-15 -15
107% 107%
-424%
- Selling and Administrative Expenses 78 78
0% 0%
2,204%
- Research and Development Expense 489 489
43% 43%
13,781%
-582 -582
203% 203%
-16,408%
- Depreciation and Amortization 19 19
49% 49%
524%
EBIT (Operating Income) EBIT -601 -601
193% 193%
-16,932%
Net Profit -599 -599
192% 192%
-16,887%

In millions USD.

Don't miss a Thing! We will send you all news about Arrowhead Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arrowhead Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
6 days ago
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. Arrowhead also filed recently a request for regulatory clearance to initiate a clinical...
Neutral
Business Wire
9 days ago
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 13, 2024, the Company's Board of Directors approved “inducement” grants to 20 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 44,35...
Neutral
Business Wire
18 days ago
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company's investigational RNA interference (RNAi) therapeutic targeting complement factor B being developed as a potential treatment for complement mediated diseases. The data were presented today, December 11, 2024, at the ...
More Arrowhead Pharmaceuticals, Inc. News

Company Profile

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Head office United States
CEO Christopher Anzalone
Employees 609
Founded 1989
Website www.arrowheadpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today